US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

By getting their drugs off the shortage list, Lilly and Novo aim to curtail the market of ... "We suspect that some patients may want branded product, but challenges with coverage or actually getting ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...

They will share their combined top-10 list for launch considerations along with operational ... a proven blueprint for success in launching a new pharmaceutical product covering commercial analytics ...

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY IncreaseRecord Revenues Driven by Continued Organic Growth in its Rare ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

The company applied for the price under the provisions of Drugs Prices Control Order, 2013 since they are an existing manufacturer of cholecalciferol tablets and capsules 60000 IU, which is a ...

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...